Background and Data

Whitehawk Therapeutics presented a real‑world data analysis at ASCO 2026 demonstrating that SEZ6 expression is markedly elevated in small‑cell lung cancer (SCLC) and other neuroendocrine tumors. The analysis highlights that SEZ6 is more abundantly expressed in tumor tissue than both established and emerging ADC targets. Because the findings are derived from actual patient specimens, the data are highly credible.

Comparison of SEZ6 with Existing Targets

SEZ6 expression showed a positive correlation with DLL3, an ADC target that is already approved. DLL3 is currently leveraged in SCLC drug development, and the association suggests that SEZ6 could be applicable to a broader patient population. Antibody‑drug conjugates (ADCs) rely on antibodies binding to specific surface proteins on cancer cells to deliver cytotoxic payloads, making target selection critical.

Therapeutic Strategy and Combination Potential

Whitehawk is developing the SEZ6‑directed ADC HWK‑206 and is evaluating combination strategies that exploit concurrent SEZ6 and DLL3 expression. Combination therapy may overcome resistance and generate synergistic activity. Consequently, HWK‑206 has the potential to serve not only as a monotherapy but also as a key component of combination regimens.

Market and Investment Implications

Therapeutic options for SCLC and neuroendocrine tumors remain limited, creating substantial demand for novel targeted agents. An SEZ6‑based ADC offers a differentiated mechanism of action that could deliver significant clinical value upon market entry. This development is poised to markedly enhance the overall value of Whitehawk’s pipeline.